Compare Adaptive Biotechnologies Corp (ADPT) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Fiverr International Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $20.16 (market cap $3.33B), while Fiverr International Ltd trades at $10.85 (market cap $403.37M). The key difference: Adaptive Biotechnologies Corp is far larger — about 8.3× Fiverr International Ltd's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| ADPT | FVRR | |
|---|---|---|
Market Cap | $3.33B | $403.37M |
Sector | Health | Industrials |
52-Week High | $22.37 | $27.77 |
52-Week Low | $10.24 | $9.62 |
Enterprise Value | $3.19B | $133.97M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Fiverr International (FVRR) trades at $11.22, up 3.79% today, showing signs of recovery from recent lows. The stock appears fundamentally undervalued with a P/E of 14.44 and P/S of 0.96, while revenue growth has been steady from $337M in 2022 to $431M in 2025. Recent earnings show mixed results with Q1 2026 missing expectations, but technical indicators suggest bullish momentum with strong moving average support.
FVRR presents a contrarian opportunity with attractive valuation metrics and improving profitability, though investor sentiment remains cautious due to active buyer declines and ongoing legal investigations. The company's strategy shift and strong gross margins of 81.86% provide upside potential, but competitive pressures and execution risks require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
